Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer
Author:
Affiliation:
1. The Beatson West of Scotland Cancer Centre; Glasgow UK
2. University Hospital Ayr; Ayr UK
3. The University of Glasgow; Glasgow UK
Publisher
Wiley
Subject
Urology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14025/fullpdf
Reference12 articles.
1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004
2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study;Berthold;J Clin Oncol,2008
3. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016
4. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the “Real World”? A Systematic Review;European Urology Oncology;2024-02
2. Far from the truth: Real‐world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification;International Journal of Urology;2023-07-11
3. Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?;Nature Reviews Urology;2022-12-12
4. Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis;Urologic Oncology: Seminars and Original Investigations;2022-11
5. Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis;European Journal of Medical Research;2022-08-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3